Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method

Journal of Clinical Pharmacy and Therapeutics

Volumn 30, Issue 2, 2005, Pages 121-132

  Desfrere, Luc ^a   Zohar, S ^b   Morville, P ^c   Brunhes, A ^a   Chevret, S ^b   Pons, G ^a   Moriette, G ^a   Rey, E ^a   Treluyer, J M ^a  

^a Université René Descartes ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c AMERICAN MEMORIAL HOSPITAL   (France)

Author keywords

Bayesian design; Continual reassessment method; Dose ranging study; Ductus arteriosus; Ibuprofen; Premature neonate

Indexed keywords

IBUPROFEN;

ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURESIS; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HUMAN; KIDNEY DISEASE; MALE; NEWBORN; OLIGURIA; PATENT DUCTUS ARTERIOSUS; PREMATURE LABOR; SIDE EFFECT; WEIGHT GAIN;

BAYES THEOREM; CLINICAL TRIALS, PHASE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DUCTUS ARTERIOSUS, PATENT; HUMANS; IBUPROFEN; INFANT; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; INJECTIONS, INTRAVENOUS; INTENSIVE CARE UNITS, NEONATAL; KIDNEY FUNCTION TESTS; PATIENT SELECTION; STATISTICS; TREATMENT OUTCOME;

EID: 27744554000     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2005.00630.x     Document Type: Article

References (38)

1. Investigators of the Vermont-Oxford Trials Network Database Project (1993) The Vermont-Oxford Trials Network: very low birth weight outcomes for 1990. Pediatrics, 91, 540-545.
2. Hammerman C (1995) Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clinics in Perinatology, 22, 457-479.
3. Lagercrantz H, Katz-Salamon M, Forssberg H (1997) The Stockholm Neonatal Project: neonatal mortality and morbidity at the Children's Centre, Karolinska Hospital. Acta Paediatrica. Supplement, 419, 11-15.
4. Brown ER (1979) Increased risk of bronchopulmonary dysplasia in infants with patent ductus arteriosus. Journal of Pediatrics, 95 (Pt 2), 865-866.
5. Evans N, Kluckow M (1996) Early ductal shunting and intraventricular haemorrhage in ventilated preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition, 75, F183-F186.
6. Cassady G, Crouse DT, Kirklin JW et al. (1989) A randomized, controlled trial of very early prophylactic ligation of the ductus arteriosus in babies who weighed 1000 g or less at birth. New England Journal of Medicine, 320, 1511-1516.
7. Jacob J, Gluck L, DiSessa T et al. (1980) The contribution of PDA in the neonate with severe RDS. Journal of Pediatrics, 96, 79-87.
8. Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE (1976) Pharmacologic closure of patent ductus arteriosus in the premature infant. New England Journal of Medicine, 295, 526-529.
9. Clyman RI (1996) Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. Journal of Pediatrics, 128 (Pt 1), 601-607.
10. Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS (1983) Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics, 102, 895-906.
11. Van Overmeire B, Smets K, Lecoutere D et al. (2000) A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. New England Journal of Medicine, 343, 674-681.
12. Lago P, Bettiol T, Salvadori S et al. (2002) Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. European Journal of Pediatrics, 161, 202-207.
13. Narayanan M, Cooper B, Weiss H, Clyman RI (2000) Prophylactic indomethacin: factors determining permanent ductus arteriosus closure. Journal of Pediatrics, 136, 330-337.
14. van Bel F, Guit GL, Schipper J, van de Bor M, Baan J (1991) Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging. Journal of Pediatrics, 118 (Pt 1), 621-626.
15. Betkerur MV, Yeh TF, Miller K, Classer RJ, Pildes RS (1981) Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics, 68, 99-102.
16. Grosfeld JL, Chaet M, Molinari F et al. (1996) Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin. Annals of Surgery, 224, 350-355; discussion 355-357.
17. Edwards AD, Wyatt JS, Richardson C et al. (1990) Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet, 335, 1491-1495.
18. McCormick DC, Edwards AD, Brown GC et al. (1993) Effect of indomethacin on cerebral oxidized cytochrome oxidase in preterm infants. Pediatric Research, 33, 603-608.
19. Varvarigou A, Bardin CL, Beharry K, Chemtob S, Papageorgiou A, Aranda JV (1996) Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA, 275, 539-544.
20. Van Overmeire B, Follens I, Hartmann S, Creten WL, Van Acker KJ (1997) Treatment of patent ductus arteriosus with ibuprofen. Archives of Disease in Childhood. Fetal and Neonatal Edition, 76, F179-F184.
21. Speziale MV, Allen RG, Henderson CR, Barrington KJ, Finer NN (1999) Effects of ibuprofen and indomethacin on the regional circulation in newborn piglets. Biology of the Neonate, 76, 242-252.
22. Patel J, Roberts I, Azzopardi D, Hamilton P, Edwards AD (2000) Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatric Research, 47, 36-42.
23. Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli FF (1999) Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. Journal of Pediatrics, 135, 733-738.
24. Mosca F, Bray M, Lattanzio M, Fumagalli M, Tosetto C (1997) Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. Journal of Pediatrics, 131, 549-554.
25. Van Overmeire B, Touw D, Schepens PJ, Kearns GL, van den Anker JN (2001) Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clinical Pharmacology and Therapeutics, 70, 336-343.
26. Aranda JV, Varvarigou A, Beharry K et al. (1997) Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatrica, 86, 289-293.
27. Sheiner LB, Beal SL, Sambol NC (1989) Study designs for dose-ranging. Clinical Pharmacology and Therapeutics, 46, 63-77.
28. Thall PF, Lee JJ, Tseng CH, Estey EH (1999) Accrual strategies for phase I trials with delayed patient outcome. Statistics in Medicine, 18, 1155-1169.
29. Kliegman RM, Fanaroff AA (1984) Necrotizing enterocolitis. New England Journal of Medicine, 310, 1093-1103.
30. Papile LA, Burstein J, Burstein R, Koffler H (1978) Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Journal of Pediatrics, 92, 529-534.
31. Rey E, Pariente-Khayat A, Gouyet L et al. (1994) Stereoselective disposition of ibuprofen enantiomers in infants. British Journal of Clinical Pharmacology, 38, 373-375.
32. O'Quigley J, Pepe M, Fisher L (1990) Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46, 33-18.
33. Zohar S, Chevret S (2001) The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. Statistics in Medicine, 20, 2827-2843.
34. Zohar S, Latouche A, Taconnet M, Chevret S (2003) Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules. Computer Methods and Programs in Biomedicine, 72, 117-125.
35. Gournay V, Savagner C, Thiriez G, Kuster A, Roze JC (2002) Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet, 359, 1486-1488.
36. Cooper-Peel C, Brodersen R, Robertson A (1996) Does ibuprofen affect bilirubin-albumin binding in newborn infant serum? Pharmacology and Toxicology, 79, 297-299.
37. Van Overmeire B, Vanhagendoren S, Schepens PJ, Ahlfors CE (2004) The influence of ibuprofen-lysine on unbound bilirubin plasma levels in preterm neonates. Pediatric Research, 55 (Pt 2), 474A.
38. Ahlfors CE (2004) Effect of ibuprofen on bilirubin-albumin binding. Journal of Pediatrics, 144, 386-388.